Effects of intravitreal bevacizumab (Avastin) on the porcine retina

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 12, 2011, Pages 1821-1829

  Iandiev, Ianors ^a   Francke, Mike ^a   Makarov, Felix ^b   Hollborn, Margrit ^a   Uhlmann, Susann ^a   Wurm, Antje ^a   Savvinov, Alexey ^c   Kohen, Leon ^a,d   Reichenbach, Andreas ^a   Wiedemann, Peter ^a   Pannicke, Thomas ^a   Bringmann, Andreas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d HELIOS Klinikum Aue   (Germany)

Author keywords

Kir4.1; M ller cell; Retina; Vascular endothelial growth factor

Indexed keywords

AQUAPORIN 1; AQUAPORIN 4; BEVACIZUMAB; CASPASE 3; CASPASE 9; EYE PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; MESSENGER RNA; PROTEIN BAX; PROTREIN KIR4.1; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL TISSUE; APOPTOSIS; AQUAPORIN 1 GENE; AQUAPORIN 2 GENE; ARTICLE; CASPASE 3 GENE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRON MICROSCOPY; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GLIAL FIBRILLARY ACIDIC PROTEIN GENE; IMMUNOHISTOCHEMISTRY; KIR4.1 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BAX GENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RETINA; SINGLE DRUG DOSE; ULTRASTRUCTURE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 GENE; VIMENTIN GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BIOLOGICAL MARKERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIOSIS; INTRAVITREAL INJECTIONS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RNA, MESSENGER; SUS SCROFA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856268421     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1773-y     Document Type: Article

References (36)

1. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312 (Pubitemid 20066717)
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309 (Pubitemid 20066716)
3. AdamisAP,Miller JW, BernalMT,D'Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450 (Pubitemid 24307211)
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487 (Pubitemid 24356306)
5. Marmor MF (1999) Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 97:239-249
6. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA (1999) Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 97:217-228
7. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373-385 (Pubitemid 34171588)
8. EichlerW, Yafai Y,Wiedemann P, Fengler D (2006) Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 12:2645-2660
9. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW (2003) Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 19:442-445
10. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37:1-12 (Pubitemid 44288601)
11. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX (2006) Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 20:323-325 (Pubitemid 46671158)
12. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A (2006) Müller cells in the healthy and diseased retina. Prog Retin Eye Res 25:397-424 (Pubitemid 44038611)
13. Mori F, Hikichi T, Takahashi J, Nagaoka T, Yoshida A (2002) Dysfunction of active transport of blood-retinal barrier in patients with clinically significant macular edema in type 2 diabetes. Diabetes Care 25:1248-1249
14. Nagelhus EA, Horio Y, Inanobe A, Fujita A, Haug FM, Nielsen S, Kurachi Y, Ottersen OP (1999) Immunogold evidence suggests that coupling of K+ siphoning and water transport in rat retinal Müller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. GLIA 26:47-54 (Pubitemid 29103167)
15. Stamer WD, Bok D, Hu J, Jaffe GJ, McKay BS (2003) Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement. Invest Ophthalmol Vis Sci 44:2803-2808 (Pubitemid 36618447)
16. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361-372 (Pubitemid 44279358)
17. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368-1370 (Pubitemid 41638883)
18. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339 (Pubitemid 41073113)
19. Rosenfeld PJ, Moshfegi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335 (Pubitemid 41073112)
20. Penha FM, Rodrigues EB, Maia M, Furlani BA, Regatieri C, Melo GB, Magalhães O Jr, Manzano R, Farah ME (2010) Retinal and ocular toxicity in ocular application of drugs and chemicals -part II: retinal toxicity of current and new drugs. Ophthalmic Res 44:205-224
21. Chiang A, Regillo CD (2011) Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 22:199-204
22. The CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
23. Yasuhara T, Shingo T, Date I (2004) The potential role of vascular endothelial growth factor in the central nervous system. Rev Neurosci 15:293-307 (Pubitemid 39388339)
24. Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26:943-954 (Pubitemid 39273068)
25. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773-1781 (Pubitemid 351261365)
26. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann RO (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421-428 (Pubitemid 29370392)
27. Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G (2008) Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 49:3164-3171
28. Pfaffl M (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002-2007
29. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, Osborne NN, Reichenbach A (2009) Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res 28:423-451
30. Klettner A, Roider J (2008) Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523-4527
31. Wang B, Atherton P, Patel R, Manning G, Donnelly R (2010) Antiangiogenic effects and transcriptional regulation of pigment epithelium-derived factor in diabetic retinopathy. Microvasc Res 80:31-36
32. Liu XQ, Kobayashi H, Jin ZB, Wada A, Nao-I N (2007) Differential expression of Kir4.1 and aquaporin 4 in the retina from endotoxin-induced uveitis rat. Mol Vis 13:309-317 (Pubitemid 46336469)
33. Zhang B, Hu Y, Ma JX (2009) Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. Invest Ophthalmol Vis Sci 50:3943-3952
34. Rezaei KA, Toma HS, Cai J, Penn JS, Sternberg P, Kim SJ (2011) Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Invest Ophthalmol Vis Sci 52:701-707
35. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tübingen Bevacizumab Study Group, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995-1002
36. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7:171-181